Clinical trial · no report yet · Phase 1/Phase 2
START-001
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- NCT05592626 ↗
- Recruiting
- Marengo Therapeutics, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Advanced Solid Tumors; Genital Neoplasm, Female; Urogenital Neoplasms; Lung Neoplasm; Neoplasms by Site; Papillomavirus Infection; Epstein-Barr Virus Infections; Carcinoma; Neoplasms; Vulvar Neoplasms; Vulvar Diseases; Abdominal Neoplasm; NSCLC (Non-small Cell Lung Cancer); Colorectal Cancer
- Interventions
- STAR0602; Irinotecan (Camptosar); Docetaxel (Taxotere)
- Arms
- Phase 1: Advanced Solid Tumors · Experimental
- Phase 2: Advanced Solid Tumors · Experimental
- Enrollment
- 366 (estimated)
- Primary outcomes
- Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1
- Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)
- Sponsor
- Marengo Therapeutics, Inc.
- Start
- Jan 4, 2023
- Primary completion
- Sep 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05592626 · updated Aug 11, 2026